Axel Bex

24.7k citations

341 papers · 14.8k indexed · 11 hit papers · h-index 53

Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment 240
Cancer Research top 0.2%
- Cancer Genomics and Diagnostics 84
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 41
- Pancreatic and Hepatic Oncology Research 19
Molecular Biology top 0.5%
- Renal and related cancers 140
Surgery top 0.5%
- Bladder and Urothelial Cancer Treatments 96
- Urinary and Genital Oncology Studies 17
Economics and Econometrics
- Economic and Financial Impacts of Cancer 30

Co-authors: Thomas Powles Karim Bensalah Börje Ljungberg Lorenzo Marconi Saeed Dabestani Thomas Lam Fabian Hofmann Alessandro Volpe
Cited by: Pulmonary and Respiratory Medicine Cancer Research Oncology
Journals: European Urology (47 papers)Journal of Clinical Oncology (29 papers)World Journal of Urology (22 papers)
Partner nations: Netherlands United Kingdom Germany

In The Last Decade

Axel Bex

320 papers receiving 14.7k citations

Hit Papers

11 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2025 European Urology
2024 Annals of Oncology
2024 The Lancet
2022 European Urology
2019 European Urology
2019 Annals of Oncology
2018 European Urology
2018 JAMA Oncology
2016 Annals of Oncology
2015 European Urology
2015 European Urology

Peers

Countries citing papers authored by Axel Bex

Since Specialization

Citations

This map shows the geographic impact of Axel Bex's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Bex with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Bex more than expected).

Fields of papers citing papers by Axel Bex

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Bex. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Bex. The network helps show where Axel Bex may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Axel Bex, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Axel Bex Line = papers co-authored together Axel Bex links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra‐operative detection and translational research British Journal of Urology ·Annette Harman,Gijs H. KleinJan,Teele Kuusk,Robert M. Verdijk,Esther Wit,Bas W.G. van Rhijn,Axel Bex,Laura S. Mertens	2025	1
2	Caval thrombectomy a urological leap into the unknown – a call for action British Journal of Urology ·Martin J. Connor,David Nicol,Laura J Panko,Faiz Mumtaz,Axel Bex,Peter Hill,Archie Hughes‐Hallett	2025	0
3	Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma Annals of Oncology ·Brian I. Rini,Laurence Albigès,Xiaobin Tang,Hartmut Koeppen,Axel Bex,H Blatt,Robert G. Uzzo,Habib Hamidi,Zoe J. Assaf,Peng North,G. Zapfel,Κωνσταντίνος Αβδελίδης,Pål Kristian Selbo,Romain Banchereau,Wenxin Xu,Mahrukh Huseni	2025	0
4	PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients European Urology Open Science ·N. V. Maslov,Patricia Zondervan,Rob Kessels,Johannes Berkhof,Maureen J.B. Aarts,Paul Hamberg,Marine Mosulishvili,AN. Kästner,Bart Rikhof,Britt B.M. Suelmann,Metin Tascilar,А. Ю. Борисов,Paul C.M.S. Verhagen,Hans M. Westgeest,محمد سلامة,Axel Bex,Adriaan D. Bins	2024	1
5	Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review Critical Reviews in Oncology/Hematology ·R Donald Hardy,Earlene Viano,Filippo Spreafico,Barbara Selle,Tanzina Chowdhury,Norbert Graf,Arnauld Verschuur,D. Gonzalez-Duque,Axel Bex,James I. Geller,Godelieve A.M. Tytgat,Marry M. van den Heuvel‐Eibrink	2024	0
6	Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Journal of Clinical Oncology ·Laurence Albigès,Axel Bex,Cristina Suárez,Robert G. Uzzo,Xiaobin Tang,Zoe J. Assaf,Sarita Dubey,Erik T. Goluboff,Corey Carter,Romain Banchereau,Ibnu Afri Hamzah,Sumanta K. Pal,Brian I. Rini	2024	27
7	Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide study SHILAP Revista de lepidopterología ·محمد سلامة,Melinda S. Schuurman,Дарвишев Азизбек Ботиржон Угли,Brunolf W. Lagerveld,Adistie Nucke Arista Dewi,Ruth Zwicker,Harrie P. Beerlage,R. Jeroen A. van Moorselaar,Niels M. Graafland,Axel Bex,Katja K.H. Aben,Patricia Zondervan	2023	5
8	NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot assisted partial nephrectomy European Urology Open Science ·Joana B. Neves,Rebecca V. Morgan,K. A. R. B. Pietraszewski,Alaul Alam,Zeynep Eleman,Menelaos Pavlou,Miles Walkden,Mahmoud Abumarzouq,Eduardo Teixeira Mota Júnior,Dominique Atmodjo-Watkins,L.L. Shcheglova,Steven Bandula,Elena Pizzo,Veronica Ranieri,Norman Williams,Steven St. Lucia,Kurinchi Selvan Gurusamy,Mark Emberton,Axel Bex,Maxine Tran	2023	1
9	A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R‐COS) SHILAP Revista de lepidopterología ·Steven MacLennan,Lisa M. Wintner,Katharina Beyer,加藤総夫,Lei Jiang,Saeed Dabestani,Lorenzo Marconi,Rachel Giles,J. Martins,Mieke Van Hemelrijck,Axel Bex,Patricia Zondervan	2023	5
10	MRI Characteristics of Pediatric and Young-Adult Renal Cell Carcinoma: A Single-Center Retrospective Study and Literature Review Cancers ·Earlene Viano,Ronald R. de Krijger,Rutger A. J. Nievelstein,Axel Bex,Aart J. Klijn,Marry M. van den Heuvel‐Eibrink,Annemieke S. Littooij	2023	3
11	Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019 British Journal of Urology ·Samantha Conroy,James W.F. Catto,Axel Bex,Janet E. Brown,Jon Cartledge,Alison Fielding,Robert J. Jones,Vincent Khoo,David Nicol,Grant D. Stewart,Mark Sullivan,Maxine Tran,J. Martins,Marcus Cumberbatch	2023	2
12	Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis World Journal of Urology ·Erika Christina Bergamaschi,N V Mutonen,Lorenzo Marconi,G Heuyer,Faridi S. van Etten‐Jamaludin,Brunolf W. Lagerveld,Axel Bex,Patricia Zondervan	2022	10
13	What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy Pure Amsterdam UMC ·Patricia Zondervan,Axel Bex	2022	4
14	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Apollo (University of Cambridge) ·Bhavna Oza,Tim Eisen,Eleni Frangou,Grant D. Stewart,Axel Bex,A.W.S. Ritchie,Richard Kaplan,J. P. Lipton,Ian D. Davis,Martin R. Stockler,Laurence Albigès,Bernard Escudier,James Larkin,Steven Joniau,Barry W. Hancock,Gregers G. Hermann,Joaquim Bellmunt,Mahesh Parmar,Patrick Royston,Angela Meade	2022	10
15	Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma SHILAP Revista de lepidopterología ·Charles Van Praet,J. Boss-Nielsen,Nikhil Vasdev,Sylvie Rottey,Valérie Fonteyne,Iulia Andraș,Maarten Albersen,Gert De Meerleer,Axel Bex,Karel Decaestecker	2021	16
16	Outcome after resection of isolated single- or oligometastatic lymph node metastases at the time of nephrectomy European Urology Open Science ·Teele Kuusk,Patricia Zondervan,Brunolf W. Lagerveld,Barak Rosenzweig,A. Raman,Union Des Forces Democratiques Rwandaises,Olavo Faitanin Caldas,Niels M. Graafland,Kees Hendricksen,Umberto Capitanio,Andrea Minervini,Stephen R. Grant,Ali Pourganjalikhan,Simon Horenblas,Axel Bex	2020	0
17	Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges? European Urology Oncology ·Maria Carmen Mir,Laurence Albigès,Axel Bex,Milan Hora,Gianluca Giannarini,Alessandro Volpe,Morgan Rouprêt	2020	2
18	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis European Urology Focus ·Saeed Dabestani,Christian Beisland,Grant D. Stewart,Karim Bensalah,Eirikur Guðmundsson,Thomas Lam,Afiza Suriani Sarimin,Paimaun Zakikhani,Lorenzo Marconi,Sergio Fernandéz‐Pello,Mariana Harasawa,Samuel P. Williams,Christian Torbrand,Thomas Powles,Erik van Werkhoven,Richard P. Meijer,Alessandro Volpe,Michael Staehler,Börje Ljungberg,Axel Bex	2018	65
19	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer Clinical Cancer Research ·Grant D. Stewart,Fiach C. O’Mahony,Alexander Laird,Lél Eöry,ByeongHoHam,Alan Mackay,Jyoti Nanda,Marie O’Donnell,Peter Mullen,S. Alan McNeill,Antony C. P. Riddick,Daniel M. Berney,Axel Bex,Michael Aitchison,Ian M. Overton,David J. Harrison,Thomas Powles	2015	29
20	Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients Clinical Cancer Research ·Arjan W. Griffioen,شقایق پژوه,Annemarie M.A. de Graaf,Patrycja Nowak‐Sliwinska,Eliézer Biao Iboukoun,F. A.,Florry A. Vyth‐Dreese,Judy R. van Beijnum,Axel Bex,Eric Jonasch	2012	125

About Axel Bex

Axel Bex is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Urology and Surgery, having authored 341 papers that have together received 14.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (240 papers), Renal and related cancers (140 papers), Bladder and Urothelial Cancer Treatments (96 papers), Cancer Genomics and Diagnostics (84 papers), Cancer Immunotherapy and Biomarkers (41 papers), Economic and Financial Impacts of Cancer (30 papers), Pancreatic and Hepatic Oncology Research (19 papers) and Urinary and Genital Oncology Studies (17 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (10.9k citations), Cancer Research (3.4k citations), Oncology (3.6k citations), Molecular Biology (7.5k citations) and Surgery (3.9k citations). Axel Bex has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Thomas Powles, Karim Bensalah, Börje Ljungberg, Lorenzo Marconi, Saeed Dabestani, Thomas Lam, Fabian Hofmann, Alessandro Volpe, Milan Hora and Michael Staehler. Their work appears in journals such as European Urology, Journal of Clinical Oncology, World Journal of Urology, British Journal of Urology and European Urology Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact